UK Markets open in 4 hrs 16 mins

GenSight Biologics S.A. (GSGTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.75000.0000 (0.00%)
At close: 10:32AM EDT
Full screen
Loading interactive chart…
  • Business Wire

    GenSight Biologics: Annual General Meeting on May 25, 2022

    PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).

  • Business Wire

    GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

    PARIS, April 29, 2022--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0390.

  • Business Wire

    GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

    PARIS, April 21, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and revenues as of March 31, 2022.